Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Stomach Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma 1Neoplasms 1Melanoma 1Liposarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1

Interventions

selpercatinib 3Trastuzumab 2Radiotherapy 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trametinib 1tovorafenib 1tipifarnib 1sargramostim 1pralsetinib 1mercaptoundecahydrododecaborate 1entrectinib 1dabrafenib 1cobimetinib 1alectinib 1aldesleukin 1Vemurafenib 1Taxes 1Tamoxifen 1Ritonavir 1Paclitaxel 1Nivolumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Famotidine 1Doxorubicin 1Cisplatin 1Bortezomib 14-boronophenylalanine-fructose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × Famotidine × Gastrointestinal × Clear all
NCT00451880 2011-10-13

Study of XL281 in Adults With Solid Tumors

Exelixis

Phase 1 Completed
180 enrolled
DermatologicEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡